4 [8] R. A. Herzlinger, S. R. Kandall, and H. G. Vaughan Jr., “Neona- tal seizures associated with narcotic withdrawal,” Journal of Pediatrics, vol. 91, no. 4, pp. 638–641, 1977. [9] S. R. Kandall and L. M. Gartner, “Late presentation of drug withdrawal symptoms in newborns,” American Journal of Diseases of Children, vol. 127, no. 1, pp. 58–61, 1974. [10] C. Zelson, S. J. Lee, and M. Casalino, “Neonatal narcotic addiction. Comparative eﬀects of maternal intake of heroin and methadone,” New England Journal of Medicine, vol. 289, no. 23, pp. 1216–1220, 1973. [11] C. Zelson, E. Rubio, and E. Wasserman, “Neonatal narcotic addiction: 10 year observation,” Pediatrics, vol. 48, no. 2, pp. 178–189, 1971. [12] I. J. Chasnoﬀ, R. Hatcher, and W. J. Burns, “Early growth patterns of methadone-addicted infants,” American Journal of Diseases of Children, vol. 134, no. 11, pp. 1049–1051, 1980. [13] C. Kuschel, “Managing drug withdrawal in the newborn infant,” Seminars in Fetal and Neonatal Medicine, vol. 12, no. 2, pp. 127–133, 2007. [14] A. Martinez, B. Kastner, and H. William Taeusch, “Hyper- phagia in neonates withdrawing from methadone,” Archives of Disease in Childhood, vol. 80, no. 3, pp. F178–F182, 1999. [15] S. M. Weinberger, S. R. Kandall, and T. M. Doberczak, “Early weight-change patterns in neonatal abstinence,” American Journal of Diseases of Children, vol. 140, no. 8, pp. 829–832, 1986. [16] L. Burns, E. Conroy, and R. P. Mattick, “Infant mortality among women on a methadone program during pregnancy,” Drug and Alcohol Review, vol. 29, no. 5, pp. 551–556, 2010. [17] G. K. Hulse, E. Milne, D. R. English, and C. D. J. Holman, “Assessing the relationship between maternal opiate use and neonatal mortality,” Addiction, vol. 93, no. 7, pp. 1033–1042, 1998. [18] S. K. Lam, W. K. To, S. J. Duthie, and H. K. Ma, “Narcotic addiction in pregnancy with adverse maternal and perinatal outcome,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 32, no. 3, pp. 216–221, 1992. [19] E. M. Ostrea, A. R. Ostrea, and P. M. Simpson, “Mortality within the ﬁrst 2 years in infants exposed to cocaine, opiate, or cannabinoid during gestation,” Pediatrics, vol. 100, no. 1, pp. 79–83, 1997. [20] S. L. Ward, D. B. Bautista, M. S. Woo et al., “Responses to hypoxia and hypercapnia in infants of substance-abusing mothers,” Journal of Pediatrics, vol. 121, no. 5 I, pp. 704–709, 1992. [21] J. G. Wingkun, J. S. Knisely, S. H. Schnoll, and G. R. Gutcher, “Decreased carbon dioxide sensitivity in infants of substance- abusing mothers,” Pediatrics, vol. 95, no. 6, pp. 864–867, 1995. [22] L. P. Finnegan, J. F. Connaughton, R. E. Kron, and J. P. Emich, “Neonatal abstinence syndrome: assessment and management,” Addictive Diseases, vol. 2, no. 1-2, pp. 141–158, 1975. [23] M. T. Crocetti, D. D. Amin, and L. M. Jansson, “Variability in the evaluation and management of opiate-exposed newborns in Maryland,” Clinical Pediatrics, vol. 46, no. 7, pp. 632–635, 2007. [24] K. Johnson, C. Gerada, and A. Greenough, “Treatment of neonatal abstinence syndrome,” Archives of Disease in Childhood, vol. 88, no. 1, pp. F2–F5, 2003. [25] J. Oei and K. Lui, “Management of the newborn infant aﬀected by maternal opiates and other drugs of dependency,” Journal of Paediatrics and Child Health, vol. 43, no. 1-2, pp. 9–18, 2007. [26] M. J. O’Grady, J. Hopewell, and M. J. White, “Management of neonatal abstinence syndrome: a national survey and review International Journal of Pediatrics of practice,” Archives of Disease in Childhood, vol. 94, no. 4, pp. F249–F252, 2009. [27] D. A. Osborn, M. J. Cole, and H. E. Jeﬀery, “Opiate treatment for opiate withdrawal in newborn infants,” Cochrane Database of Systematic Reviews, no. 10, article CD002059, 2010. [28] D. A. Osborn, H. E. Jeﬀery, and M. J. Cole, “Sedatives for opiate withdrawal in newborn infants,” Cochrane Database of Systematic Reviews, no. 10, article CD002053, 2010. [29] S. Sarkar and S. M. Donn, “Management of neonatal absti- nence syndrome in neonatal intensive care units: a national survey,” Journal of Perinatology, vol. 26, no. 1, pp. 15–17, 2006. [30] NSW Department of Health, Intergovernmental Committee on Drugs, Ministerial Council on Drug Strategy, National Clinical Guidelines for the Management of Drug Use during Pregnancy, Birth and the Early Developmental Years of the Newborn, NSW Department of Health, Sydney, Australia, 2006. [31] N. S. Seligman, N. Salva, E. J. Hayes, K. C. Dysart, E. C. Pequignot, and J. K. Baxter, “Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates,” American Journal of Obstetrics and Gynecology, vol. 199, no. 4, pp. 396.e1–396.e7, 2008. [32] W. O. Farid, S. A. Dunlop, R. J. Tait, and G. K. Hulse, “The eﬀects of maternally administered methadone, buprenorphine and naltrexone on oﬀspring: review of human and animal data,” Current Neuropharmacology, vol. 6, no. 2, pp. 125–150, 2008. [33] K. Kaltenbach and L. P. Finnegan, “Perinatal and develop- mental outcome of infants exposed to methadone in-utero,” Neurotoxicology and Teratology, vol. 9, no. 4, pp. 311–313, 1987. [34] E. K. Enters, H. Guo, U. Pandey, D. Ko, and S. E. Robinson, “The eﬀect of prenatal methadone exposure on development and nociception during the early postnatal period of the rat,” Neurotoxicology and Teratology, vol. 13, no. 2, pp. 161–166, 1991. [35] L. Niu, B. Cao, H. Zhu et al., “Impaired in vivo synaptic plasticity in dentate gyrus and spatial memory in juvenile rats induced by prenatal morphine exposure,” Hippocampus, vol. 19, no. 7, pp. 649–657, 2009. [36] L. M. Schrott, L. T. M. Franklin, and P. A. Serrano, “Prenatal opiate exposure impairs radial arm maze performance and reduces levels of BDNF precursor following training,” Brain Research, vol. 1198, no. C, pp. 132–140, 2008. [37] I. Vathy, “Eﬀects of prenatal morphine and cocaine on post- natal behaviors and brain neurotransmitters,” NIDA Research Monograph, vol. 158, pp. 88–114, 1995. [38] I. Vathy, “Prenatal opiate exposure: long-term CNS conse- quences in the stress system of the oﬀspring,” Psychoneuroen- docrinology, vol. 27, no. 1-2, pp. 273–283, 2002. [39] Y. Wang and T. Z. Han, “Prenatal exposure to heroin in mice elicits memory deﬁcits that can be attributed to neuronal apoptosis,” Neuroscience, vol. 160, no. 2, pp. 330–338, 2009. [40] C. J. Schindler, J. Velı´sˇkova´, R. Sˇ lamberova´, and I. Vathy, “Pre- natal morphine exposure alters susceptibility to bicuculline seizures in a sex- and age-speciﬁc manner,” Developmental Brain Research, vol. 121, no. 1, pp. 119–122, 2000. [41] H. Vargas-Perez, R. T. A. Kee, C. H. Walton et al., “Ven- tral tegmental area BDNF induces an opiate-dependent-like reward state in na¨ıve rats,” Science, vol. 324, no. 5935, pp. 1732–1734, 2009. [42] K. J. Meador, G. A. Baker, and N. Browning, “Cognitive func- tioning at 3 years of age after fetal exposure to antiepileptic